Welcome to our dedicated page for VERACYTE SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Veracyte, Inc. filings document the regulatory record for a Nasdaq-listed cancer diagnostics company with a portfolio that includes Decipher, Afirma, Prosigna, and bladder cancer diagnostics. The company’s Form 8-K reports primarily cover operating and financial results, preliminary financial and testing-volume estimates, and material corporate events.
Veracyte’s proxy and governance filings disclose shareholder voting matters, board and executive compensation practices, equity award information, and governance procedures. Other material-event filings address officer appointments, compensatory arrangements, capital-structure disclosures, and formal exhibits tied to financial reporting and corporate actions.
Veracyte reported strong fourth quarter and full-year 2025 results with double-digit growth and higher profitability. Q4 total revenue rose 19% to $140.6 million, with testing revenue up 21% to $135.8 million and Decipher and Afirma driving growth. Q4 GAAP net income reached $41.1 million, or 29.3% of revenue, and adjusted EBITDA was $42.3 million, or 30.1% of revenue, while operating cash flow was $52.6 million.
For 2025, total revenue increased 16% to $517.1 million and testing revenue grew 18% to $493.2 million. Full-year GAAP net income grew 175% to $66.4 million, with adjusted EBITDA up 55% to $142.5 million, or 27.6% of revenue, and operating cash flow of $136.3 million, ending the year with $412.9 million in cash, cash equivalents and short-term investments. Veracyte reiterated 2026 guidance for 10%–13% total revenue growth to $570–$582 million and expects adjusted EBITDA margin of approximately 25%.
FMR LLC filed an amended Schedule 13G reporting beneficial ownership of 5,688,209.19 shares of Veracyte, Inc. common stock, representing 7.2% of the class as of the event date 12/31/2025. This reflects a sizable institutional stake in the company.
FMR LLC reports sole voting power over 5,682,465.00 shares and sole dispositive power over 5,688,209.19 shares, with no shared voting or dispositive power. Abigail P. Johnson is also listed as a reporting person with sole dispositive power over the same 5,688,209.19 shares. The securities are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Veracyte.
Artisan Partners has filed Amendment No. 5 to report its ownership in Veracyte, Inc. The Artisan entities report beneficial ownership of 6,263,041 shares of Veracyte common stock, representing 7.9% of the class, based on 79,049,173 shares outstanding as of 10/31/2025.
The group has shared voting power over 5,457,186 shares and shared dispositive power over 6,263,041 shares, with no sole voting or dispositive power. The shares were acquired on behalf of discretionary clients of Artisan Partners Limited Partnership, and the filing states they are held in the ordinary course of business, not for the purpose of changing or influencing control of Veracyte.
Veracyte, Inc. reported preliminary, unaudited estimates for the fourth quarter and full year ended December 31, 2025. For the fourth quarter, it expects total revenue between $138 million and $140 million, testing revenue between $134 million and $136 million, and testing volume of approximately 45,500 tests. For the full year 2025, Veracyte expects total revenue between $515 million and $517 million, testing revenue between $491 million and $493 million, and testing volume of approximately 169,700 tests. The company also expects to report an adjusted EBITDA margin of greater than 25% for the full year. These figures are preliminary and may change after completion of year-end closing procedures and the audit of the financial statements.
ARK Investment Management LLC and its CEO and CIO Catherine D. Wood report beneficial ownership of Veracyte, Inc. common stock as of 12/31/2025. They collectively report holding 3,887,547 shares, representing 4.92% of Veracyte’s outstanding common stock.
ARK has sole voting power over 3,728,954 shares and shared voting power over 71,269 shares, with sole dispositive power over all 3,887,547 shares. Catherine D. Wood reports shared voting power over 3,800,223 shares and shared dispositive power over 3,887,547 shares. They certify the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Veracyte.
Veracyte, Inc. reported an insider stock sale by its SVP and General Counsel. On 12/16/2025, the officer sold 10,639 shares of common stock at a weighted average price of $43.1277 per share and an additional 100 shares at $43.68 per share. These transactions were made under a Rule 10b5-1 trading plan adopted on August 29, 2025, which automates trades according to preset instructions. Following these sales, the reporting person beneficially owned 67,760 shares of Veracyte common stock, held directly.
Veracyte, Inc. (VCYT) reported an insider stock sale by its Chief Commercial Officer-CLIA. On 11/25/2025, the officer sold 2,808 shares of common stock at $50 per share in a transaction coded "S" (sale). After this trade, the officer beneficially owned 86,291 shares directly. The filing notes that the transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on June 9, 2025, which is designed to allow insiders to sell shares according to a set schedule.
Veracyte, Inc. (VCYT) reported an insider stock sale by one of its directors. According to the Form 4, the director sold 1,106 shares of Veracyte common stock on 11/25/2025 at a weighted average price of $50.2493 per share, with individual trade prices ranging from $50.005 to $50.66. Following this transaction, the director now beneficially owns 29,362 shares of Veracyte common stock in direct ownership.
The filing notes that these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2024. Such plans allow insiders to sell shares according to a preset schedule or conditions, helping separate trading activity from day-to-day decisions about the company.
Veracyte, Inc. (VCYT) director stock sale reported in a Form 4 filing. A company director filed as a single reporting person and disclosed three open‑market sales of Veracyte common stock on 11/20/2025, all coded as sales. The transactions, made pursuant to a Rule 10b5-1 plan adopted on August 21, 2025, involved 1,491 shares at a weighted average price of $40.9526, 7,049 shares at a weighted average price of $42.4765, and 1,460 shares at a weighted average price of $43.2095.
After these sales, the reporting person beneficially owned 27,199 shares of Veracyte common stock, held directly. The filing notes that each weighted average price represents multiple trades within specified price ranges, and more detailed breakdowns are available to the SEC, the issuer, or a shareholder upon request.
Veracyte (VCYT) insider activity: The company’s VP and Chief Accounting Officer reported open‑market sales of common stock. On 11/07/2025, 5,818 shares were sold at a weighted average price of $40.2078. On 11/10/2025, 5,102 shares were sold at a weighted average price of $42.3321. Following these transactions, beneficial ownership stood at 38,745 shares.
The filing notes that each weighted average reflects multiple trades within disclosed price ranges, with detailed breakdowns available upon request.